AVITA Medical, Inc. (RCEL)
NASDAQ: RCEL · Real-Time Price · USD
3.690
+0.030 (0.82%)
Oct 29, 2025, 4:00 PM EDT - Market closed
AVITA Medical Stock Forecast
Stock Price Forecast
The 5 analysts that cover AVITA Medical stock have a consensus rating of "Buy" and an average price target of $11.8, which forecasts a 219.78% increase in the stock price over the next year. The lowest target is $4.00 and the highest is $21.
Price Target: $11.8 (+219.78%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for AVITA Medical stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 2 | 1 | 1 | 1 | 1 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 4 | 4 | 4 | 4 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Lake Street | Lake Street | Strong Buy → Hold Downgrades $8 → $4 | Strong Buy → Hold | Downgrades | $8 → $4 | +8.40% | Oct 17, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $14 | Strong Buy | Maintains | $14 | +279.40% | Oct 17, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $14 | Strong Buy | Maintains | $14 | +279.40% | Sep 15, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $18 → $14 | Strong Buy | Maintains | $18 → $14 | +279.40% | Sep 5, 2025 |
| Lake Street | Lake Street | Strong Buy Maintains $14 → $8 | Strong Buy | Maintains | $14 → $8 | +116.80% | Aug 11, 2025 |
Financial Forecast
Revenue This Year
77.36M
from 64.25M
Increased by 20.40%
Revenue Next Year
102.84M
from 77.36M
Increased by 32.94%
EPS This Year
-1.27
from -2.39
EPS Next Year
-0.64
from -1.27
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 82.7M | 124.4M | |||
| Avg | 77.4M | 102.8M | |||
| Low | 69.7M | 79.9M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 28.7% | 60.8% | |||
| Avg | 20.4% | 32.9% | |||
| Low | 8.4% | 3.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.27 | -0.13 | |||
| Avg | -1.27 | -0.64 | |||
| Low | -1.73 | -1.35 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.